Greenjaytherapeutics

GreenJay Therapeutics is a late-stage pharmaceutical company based in Houston, Texas, focused on reformulation of drugs to improve clinical outcomes. The company has developed a new intravenous formulation of busulfan called Bulanta™ that removes a toxic Class 2 solvent, which is designed to reduce toxicity risks for patients undergoing stem cell transplantation. They are pursuing FDA approval through the NDA 505(b)(2) regulatory pathway.